Solei, RIFF and Aphria medical cannabis to be
available for the PAX Era device and platform
LEAMINGTON, ON, June 7, 2019 /CNW/ - Aphria Inc. ("Aphria"
or the "Company") (TSX: APHA and NYSE: APHA) today
announced an agreement with San
Francisco-based PAX Labs, Inc. ("PAX"), a leader in
the design and development of premium cannabis vaporization
devices, that will enable Aphria to provide premium cannabis
extracts in pods designed for use with PAX's innovative Era device
and platform. The Company plans to introduce PAX pods for both
adult-use consumers and medical patients, pending anticipated
changes to the Cannabis Act to permit the sale of cannabis extracts
for vaporization.
"As Aphria continues to drive the evolution of the industry, we
are thrilled to partner with a technology leader like PAX to
provide a new avenue for consumers to integrate cannabis into their
lives," said Irwin Simon, Interim
CEO of Aphria. "We are excited to bring our premium cannabis
extracts from Solei, RIFF and our flagship medical cannabis brand,
Aphria, to the PAX Era device and platform."
PAX has already sold more than 500,000 Era devices for oil
concentrates in the United States
and continues to see expansive growth.
"The expected legalization of vapes and concentrates will mark a
significant turning point in the Canadian market, providing more
choice and new experiences, while opening the door to a range of
new consumers," added Simon. "Our strategic alliance with PAX sets
the stage for our broad portfolio of vapes and concentrate products
to come."
Aphria estimates Vapes & Concentrates will represent close
to 30% of the entire Canadian adult-use market by 2021.
"This collaboration compliments Aphria's growing roster of
strategic innovation partners, including Manna Molecular Sciences
and Rapid Dose Therapeutics, as we pursue new innovations that will
change the way consumers interact with cannabis in the future,"
said Simon.
We Have A Good Thing Growing
About Aphria Inc.
Aphria Inc. is a leading global cannabis company driven by an
unrelenting commitment to our people, the planet, product quality
and innovation. Headquartered in Leamington, Ontario – the greenhouse capital
of Canada – Aphria Inc. has been
setting the standard for the low-cost production of high-quality
cannabis at scale, grown in the most natural conditions possible.
Focusing on untapped opportunities and backed by the latest
technologies, Aphria Inc. is committed to bringing breakthrough
innovation to the global cannabis market. The Company's portfolio
of brands is grounded in expertly-researched consumer insights
designed to meet the needs of every consumer segment. Rooted in our
founders' multi-generational expertise in commercial agriculture,
Aphria Inc. drives sustainable long-term shareholder value through
a diversified approach to innovation, strategic partnerships and
global expansion, with a presence in more than 10 countries across
5 continents.
For more information, visit: aphriainc.com
CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS: Certain
information in this news release constitutes forward-looking
statements under applicable securities laws. Any statements that
are contained in this news release that are not statements of
historical fact may be deemed to be forward-looking statements.
Forward looking statements are often identified by terms such as
"may", "should", "anticipate", "expect", "potential", "believe",
"intend" or the negative of these terms and similar expressions.
Forward-looking statements in this news release include, but are
not limited to, statements with respect to the future composition
of the cannabis market. Forward-looking statements necessarily
involve known and unknown risks, including, without limitation,
risks associated with general economic conditions; adverse industry
events; marketing costs; loss of markets; future legislative and
regulatory developments involving cannabis; inability to access
sufficient capital from internal and external sources, and/or
inability to access sufficient capital on favourable terms; the
cannabis industry in Canada
generally, income tax and regulatory matters; the ability of Aphria
Inc. to implement its business strategies; competition; crop
failure; currency and interest rate fluctuations and other risks,
including those set forth in our public filings on SEDAR and
EDGAR.
Readers are cautioned that the foregoing list is not exhaustive.
Readers are further cautioned not to place undue reliance on
forward-looking statements as there can be no assurance that the
plans, intentions or expectations upon which they are placed will
occur. Such information, although considered reasonable by
management at the time of preparation, may prove to be incorrect
and actual results may differ materially from those
anticipated.
The forward-looking statements included in this news release are
made as of the date of this news release and the Company does not
undertake an obligation to publicly update such forward-looking
statements to reflect new information, subsequent events or
otherwise unless required by applicable securities laws.
Forward-looking statements contained in this news release are
expressly qualified by this cautionary statement.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/aphria-adds-to-planned-portfolio-of-vapes--concentrates-with-pax-labs-agreement-300863846.html
SOURCE Aphria Inc.